Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2002

View Archived Issues

CPI-0004Na more effective than doxorubicin against lung metastases

Combinations containing TT-232 and cytostatics examined in murine models

Clinical benefits reported for local treatment with rHuGM-CSF in skin metastases

SPD-756: metabolism and pharmacokinetics of a new NRTI

New class of P2Y12 antagonists designed at Inspire as antithrombotics

Newly discovered H3 antagonist described in further detail by Abbott

Central nAChR agonists show cognition-enhancing and analgesic effects

Selective CCK2 antagonist undergoes clinical evaluation at JB for pancreatic cancer

Topical therapeutic AIDS vaccine demonstrates antiviral efficacy in monkeys

Santarus and TAP sign license agreement related to GI diseases

MediciNova acquires worldwide rights to novel cancer treatment

Plans discussed for Exherin phase I clinical trials

Phase I trial initiated with visilizumab in patients with ulcerative colitis

Synaptic licenses alpha2-adrenergic compounds to P&G

AltaRex receives positive opinion for OvaRex as orphan drug

French researchers identify GHB receptor modulators for use in sleep disorders

BMS claims serine protease inhibitors with anticoagulant activity

Novel anti-H. pylori agents claimed in Shionogi patent

Researchers at Bayer present Maxi-K channel openers and their use in ischemic disorders

British Biotech presents novel antibacterial/antiprotozoal agents

Novartis group identifies new adenosine A2B/A3 antagonists

Merck KGaA reports MTP inhibitors and their use in lipoprotein disorders

Rosuvastatin reported to be effective and suitable for different patient populations

BioCryst streamlines operations